KAMADA LTD
Business
KAMADA LTD is a global biopharmaceutical company that develops, manufactures and commercializes specialty plasma-derived therapeutics for rare and serious conditions. Its main products include plasma‑derived immunoglobulins and protein therapeutics such as KEDRAB/KAMRAB, CYTOGAM, GLASSIA, WINRHO SDF, HEPAGAM B, VARIZIG, KAMRHO (D) and equine anti‑snake venoms, as well as investigational Inhaled AAT. The company operates two primary business segments—Proprietary Products (including plasma collection) and Distribution—and conducts R&D and manufacturing at its cGMP facility. It sells products across the United States, Canada, Israel and over 30 international markets through strategic partners, local distributors, tenders and its U.S. plasma collection centers.
Summary from filing dated 2025-03-05
Financials
Latest annual snapshot (FY2025, period end 2025-12-31). Full statement history unavailable for this entity.
| Revenue | — |
| Net income | $20.20M |
| Total assets | $378.71M |
| Total liabilities | — |
| Stockholders' equity | — |
| Operating cash flow | — |